Takeda Pharmaceutical Company Limited Reports Phase 3 Superiority of Zasocitinib vs Deucravacitinib

Takeda reported Phase 3 head-to-head data showing zasocitinib achieved statistical superiority over deucravacitinib across primary and key secondary endpoints in moderate-to-severe plaque psoriasis, with higher complete skin clearance as early as week 8 and durable responses through week 52 in othe…